Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
NCT ID: NCT04651179
Last Updated: 2021-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
33 participants
OBSERVATIONAL
2020-04-24
2021-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observation
not applicable, observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received first line treatment with HD IFO
* Following HD IFO treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria :
1. Relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability
2. Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis
3. Non resectable relapsed disease diagnosed over 24 months from the initial diagnosis Before or during GEMDOX treatment, eligible patients may have been subject to metastasectomy
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Franca Fagioli
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franca Fagioli, MD
Role: PRINCIPAL_INVESTIGATOR
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Nazionale Tumori
Milan, Milano, Italy
Fondazione del Piemonte per l' Oncologia IRCCS Candiolo
Candiolo, Turin, Italy
Istituto Ortopedico Rizzoli
Bologna, , Italy
AOUC Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
Azienda Ospedaliero Universitaria pisana
Pisa, , Italy
IRCCS Istituti Fisioterapici Ospitalieri
Rome, , Italy
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Turin, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSTEOREC/OSS
Identifier Type: -
Identifier Source: org_study_id